BPM 19211
Alternative Names: BPM-19211Latest Information Update: 25 Aug 2025
At a glance
- Originator Berg Pharma
- Developer BPG Bio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 25 Aug 2025 Discontinued for Neurological disorders in USA (unspecified route) before August 2025 (BPG Bio pipeline, August 2025)
- 09 Sep 2021 Early research in Neurological disorders in USA (unspecified route), prior to September 2021 (Berg Pharma pipeline, September 2021)